Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas

ConditionsCytokine-Induced Killer Cells Milignant Gliomas

Trial statusNot yet recruiting

Trial phasePhase 1, Phase 2

Trial typeInterventional

Biological sexAll

Age18-80

SponsorThe First People's Hospital of Changzhou

About this trial

The purpose of this study is to determine whether combining of Temozolomide and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with Malignant Gliomas. The effectiveness and safety of CIK cells for the treatment of Malignant Glioma is also evaluated.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

Temozolomide
Drug
Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
CIK
Biological/Vaccine
The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat

Treatment groups

80 Participants

are divided into 2 treatment groups

Group A: TemozolomideOther 1 intervention

Group B: Temozolomide+CIKOther 1 intervention

Trial outcomes

Primary outcomes

Overall survival

Time frame

5 years

Secondary outcomes

Adverse events

Time frame

4 weeks

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The First People's Hospital of Changzhou

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: